MRNA (MRNA)

Financial Metrics & Valuation Analysis

Enterprise Valuation (TTM)

Enterprise Value$21.26B
EV / Sales9.54
EV / EBITDA-7.23
EV / Operating Cash Flow-20.21
EV / Free Cash Flow-17.39

Return Metrics (TTM)

Return on Equity (ROE)-39.20%
Return on Assets (ROA)-28.75%
Return on Invested Capital (ROIC)-39.40%
Return on Capital Employed (ROCE)-39.40%

Yield Metrics

Earnings Yield-14.51%
Free Cash Flow Yield-5.62%

Balance Sheet Strength

Net Debt / EBITDA0.17
Current Ratio2.29
Working Capital$3.28B
Tangible Asset Value$6.76B
Net Current Asset Value$1.61B

Working Capital Efficiency

Days Sales Outstanding2.79
Days Payables Outstanding24.30
Operating Cycle (Days)43.53
Cash Conversion Cycle19.23

Capital Allocation

CapEx / Revenue7.68%
CapEx / Operating Cash Flow-16.25%
R&D / Revenue129.08%
SG&A / Revenue43.31%

Fiscal Year 2025 Ratios

Audited annual results as of 2025-12-31

Margins

Gross Profit Margin55.35%
Operating Margin-158.13%
Net Profit Margin-145.16%

Solvency

Debt / Equity0.22
Quick Ratio3.22
Cash Ratio1.31

Per Share

Revenue / Share$5.00
FCF / Share-$5.31
PE Ratio-4.06